Commercial System Effective for Cefiderocol Susceptibility Testing
|
By LabMedica International staff writers Posted on 11 Jul 2019 |

Image: The Sensititre Complete Automated Antibiotic Susceptibility Testing (AST) System performs all susceptibility testing on a single platform utilizing the superior sensitivity of true MIC results (Photo courtesy of Thermo Fisher Scientific).
The novel formulation of the cephalosporin antibiotic makes it very effective against gram-negative non-fastidious bacteria that are otherwise highly resistant to antibiotics, including carbapenem-resistant strains of Enterobacteriaceae and non-fermenters.
In microbiology, the minimum inhibitory concentration (MIC) is the lowest concentration of a chemical, usually a drug, which prevents visible growth of bacterium. MIC depends on the microorganism, the affected human being (in vivo only), and the antibiotic itself.
An international team of scientists working with Thermo Fisher Scientific (Cleveland, Ohio, USA) conducted a study that involved 374 recent clinical isolates, which included Escherichia coli, Klebsiella spp., Enterobacter spp., Citrobacter spp., Serratia marcescens, Pseudomonas aeruginosa, and Acinetobacter baumannii. One of the four study sites additionally used 147 Centers for Disease Control and Prevention challenge isolates. Three sites also used 11 reproducibility isolates, with three of these isolates being tested each day for three days. Finally, all four sites tested two quality control strains: E. coli ATCC 25922 and P. aeruginosa ATCC 27853.
The team tested a commercially prepared dried minimum inhibitory concentration (MIC) susceptibility system, the Thermo Fisher Scientific Sensititre, and demonstrated an equivalent level of performance compared with the Clinical & Laboratory Standards Institute (CLSI) M07/M100 and the International Organization for Standardization (ISO) 20776-1 reference broth microdilution (BMD) method when testing cefiderocol against Gram-negative non-fastidious organisms.
Overall agreement for the reproducibility (± 1 log2 dilution) concerning the most frequent (or modal) MIC value using automated and manual reading was 95.0% and 95.3%, respectively. The lowest agreement between the two test methods was 90.0% for Enterobacter spp., followed by 92.0% for Citrobacter spp. The strongest agreement was for P. aeruginosa (97.5%). The agreement among the four testing sites was high, at about 95%.
Thomas C. Lewis, BSc, a Research and Development Project Leader at Thermo Fisher Scientific, said, “The high level of agreement obtained by the Sensititre susceptibility system and the CLSI/ISO BMD method suggests that this is an acceptable method for susceptibility testing of cefiderocol. The results are available within 18 to 24 hours, versus several days for the broth. Plus, the testing materials can be kept on the laboratory shelf at room temperature before being used, which is a lot more convenient.” The study was presented at the Annual meeting of the American Society of Microbiology, held June 7-11, 2019, in Atlanta, GA, USA.
Related Links:
Thermo Fisher Scientific
In microbiology, the minimum inhibitory concentration (MIC) is the lowest concentration of a chemical, usually a drug, which prevents visible growth of bacterium. MIC depends on the microorganism, the affected human being (in vivo only), and the antibiotic itself.
An international team of scientists working with Thermo Fisher Scientific (Cleveland, Ohio, USA) conducted a study that involved 374 recent clinical isolates, which included Escherichia coli, Klebsiella spp., Enterobacter spp., Citrobacter spp., Serratia marcescens, Pseudomonas aeruginosa, and Acinetobacter baumannii. One of the four study sites additionally used 147 Centers for Disease Control and Prevention challenge isolates. Three sites also used 11 reproducibility isolates, with three of these isolates being tested each day for three days. Finally, all four sites tested two quality control strains: E. coli ATCC 25922 and P. aeruginosa ATCC 27853.
The team tested a commercially prepared dried minimum inhibitory concentration (MIC) susceptibility system, the Thermo Fisher Scientific Sensititre, and demonstrated an equivalent level of performance compared with the Clinical & Laboratory Standards Institute (CLSI) M07/M100 and the International Organization for Standardization (ISO) 20776-1 reference broth microdilution (BMD) method when testing cefiderocol against Gram-negative non-fastidious organisms.
Overall agreement for the reproducibility (± 1 log2 dilution) concerning the most frequent (or modal) MIC value using automated and manual reading was 95.0% and 95.3%, respectively. The lowest agreement between the two test methods was 90.0% for Enterobacter spp., followed by 92.0% for Citrobacter spp. The strongest agreement was for P. aeruginosa (97.5%). The agreement among the four testing sites was high, at about 95%.
Thomas C. Lewis, BSc, a Research and Development Project Leader at Thermo Fisher Scientific, said, “The high level of agreement obtained by the Sensititre susceptibility system and the CLSI/ISO BMD method suggests that this is an acceptable method for susceptibility testing of cefiderocol. The results are available within 18 to 24 hours, versus several days for the broth. Plus, the testing materials can be kept on the laboratory shelf at room temperature before being used, which is a lot more convenient.” The study was presented at the Annual meeting of the American Society of Microbiology, held June 7-11, 2019, in Atlanta, GA, USA.
Related Links:
Thermo Fisher Scientific
Latest Microbiology News
- New WHO Tools Address Gaps in Antimicrobial Resistance Testing
- Complete Malaria Genomes Could Improve Species Identification and Surveillance
- Point-of-Care Test Detects Tuberculosis from Tongue Swab and Sputum
- Automated Microbial Identification and Susceptibility System Gains FDA Clearance
- Gastrointestinal Flex Assay Gains EU Certification for Tailored Pathogen Testing
- Molecular Panels Gain FDA Clearance for One-Hour Gastrointestinal Pathogen Testing
- Common Genetic Variant Increases Risk of Bacterial Pneumonia
- Rapid Host-Response Assay Gains FDA Clearance to Help Distinguish Bacterial and Viral Infections
- Stool Testing Predicts UTI Risk and Guides Antibiotic Selection
- Repeat Prenatal STI Screening and Treatment May Reduce Preterm Births
- Decentralized Laboratory Network Improves Detection of Viral Hemorrhagic Fevers in Guinea
- Molecular Panel Gains WHO Emergency Use Listing to Support Ebola Outbreak Response
- Rapid Host-Response Test Aims to Predict Corticosteroid Benefit in Sepsis
- Oral and Lung Microbiome Changes Linked to Severe Long Covid Symptoms
- Study Finds Distinct Malaria Parasites Linked to Sickle Cell Trait Protection
- Rapid Urine Test Aids Diagnosis of Invasive Aspergillosis
Channels
Clinical Chemistry
view channel
Study Supports Review of Long-Term Blood-Monitoring Guidelines for Clozapine
Treatment-resistant schizophrenia (TRS) is a severe form of schizophrenia for which clozapine remains the only antipsychotic specifically approved by the U.S. Food and Drug Administration (FDA).... Read more
Plasma Assay Measures Six Amyloid Beta Peptides for Alzheimer’s Treatment Research
Alzheimer’s disease research and related neurological studies often require tools that can characterize brain amyloid pathology and amyloid beta biology. Blood-based biomarker assays may help researchers... Read more
Blood Biomarker Model May Help Estimate Five- and 10-Year Cognitive Impairment Risk
Estimating future cognitive impairment risk remains challenging in cognitively healthy adults, particularly when biomarker findings are reduced to simple positive or negative results. Because mild cognitive... Read moreMolecular Diagnostics
view channel
Protein-Based Classifier Shows Promise for Predicting Melanoma Treatment Outcomes
Immune checkpoint inhibitors have improved melanoma treatment and extended survival over the past 15 years. However, many patients do not respond, and reliable biomarkers for predicting treatment response... Read more
Liquid Biopsy Gains FDA Approval to Guide Breast Cancer Combination Therapy
Estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer accounts for approximately 70% of cases. Acquired ESR1 mutations can cause resistance to endocrine... Read moreHematology
view channel
Werfen Gains FDA Clearance for ROTEM sigma Cartridge Use in Trauma
Traumatic injuries account for approximately 10% of deaths worldwide, with uncontrolled bleeding remaining a leading cause of potentially preventable trauma-related death. Trauma-induced coagulopathy further... Read more
Serial Blood Samples Reveal Leukemia’s Evolution Decades Before Diagnosis
Acute myeloid leukemia (AML) is an aggressive blood cancer affecting approximately 2,700 people in the U.K. annually, with only about one in six patients surviving five years after diagnosis.... Read moreImmunology
view channel
Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice
Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more
Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis
Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more
Antibody Testing Informs Melioidosis Diagnosis and Surveillance in Emerging Regions
Melioidosis is a serious and sometimes fatal infection caused by the soil- and water-dwelling bacterium Burkholderia pseudomallei. People and animals can contract the disease through exposure to contaminated... Read morePathology
view channel
AI Prostate Cancer Test Added to NCCN Guidelines for Post-Surgery Recurrence
Following radical prostatectomy, an estimated 20% to 40% of prostate cancer patients develop biochemical recurrence, marked by rising prostate-specific antigen levels that may indicate cancer recurrence.... Read more
New Training Approach Helps AI Distinguish Neighboring Cells in Tissue
Artificial intelligence (AI) can assist with identifying cells in digital pathology images, but densely packed tissue remains difficult to analyze. Neighboring cells may be merged, counted twice, or missed,... Read more
Review Highlights Progress and Validation Needs for AI in Digital Pathology
Pathology remains the gold standard for disease diagnosis, but clinical laboratories face growing demands for faster, more reproducible diagnostic and prognostic workflows. Digital pathology based on whole-slide... Read moreTechnology
view channel
New qPCR Master Mixes Offer Broad Compatibility for Routine Research
Quantitative PCR (qPCR) workflows require consistent reagent performance across instruments and assay formats. Laboratories must also manage costs without changing established protocols.... Read more
Multi-Agent AI Framework Supports Laboratory Quality and Workflow Monitoring
Clinical laboratories analyze blood, urine, tissue, and other bodily fluids to support disease diagnosis and treatment. Rising test volumes, workforce shortages, and increasingly complex diagnostics are... Read moreIndustry
view channel
Labcorp Partners With Grupo Fleury to Expand Clinical Trial Operations in Brazil
Multinational clinical trials require laboratory partners that combine global expertise with local operational capabilities. Brazil is an important clinical research destination, supported by its diverse... Read more







